Q32 Bio (NASDAQ:QTTB) Upgraded at Zacks Research

Zacks Research upgraded shares of Q32 Bio (NASDAQ:QTTB) from a hold rating to a strong-buy rating in a research note released on Thursday morning,Zacks.com reports.

QTTB has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Q32 Bio in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Q32 Bio in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Q32 Bio currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.

Q32 Bio Stock Performance

Shares of NASDAQ QTTB opened at $6.82 on Thursday. The firm has a market cap of $83.89 million, a price-to-earnings ratio of 2.97 and a beta of 0.14. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.57 and a current ratio of 4.85. Q32 Bio has a 52 week low of $1.35 and a 52 week high of $7.80. The business’s 50-day simple moving average is $4.29 and its 200-day simple moving average is $3.16.

Q32 Bio (NASDAQ:QTTB) last posted its quarterly earnings results on Tuesday, March 10th. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $4.71. The business had revenue of $53.74 million for the quarter. As a group, equities research analysts expect that Q32 Bio will post -12.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Q32 Bio news, CEO Jodie Pope Morrison sold 9,896 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total value of $44,630.96. Following the completion of the sale, the chief executive officer owned 89,104 shares of the company’s stock, valued at approximately $401,859.04. This represents a 10.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 16,706 shares of company stock valued at $75,344 over the last ninety days. 40.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Q32 Bio

Hedge funds and other institutional investors have recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in shares of Q32 Bio in the 2nd quarter valued at $25,000. Acadian Asset Management LLC acquired a new position in Q32 Bio in the first quarter valued at about $50,000. Two Sigma Investments LP bought a new stake in shares of Q32 Bio in the third quarter worth about $62,000. ADAR1 Capital Management LLC acquired a new stake in shares of Q32 Bio during the fourth quarter worth about $66,000. Finally, AQR Capital Management LLC bought a new position in shares of Q32 Bio during the 1st quarter valued at about $68,000. 31.32% of the stock is owned by institutional investors.

Trending Headlines about Q32 Bio

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright raised multi-year EPS forecasts and reiterated a Buy rating with a $13 price target, trimming losses in near-term years and projecting positive earnings by FY2029–FY2030 (FY2029 $0.16; FY2030 $0.41). This institutional upgrade and target amplify upside expectations.
• Positive Sentiment: Zacks added QTTB to its Rank #1 (Strong Buy) momentum lists on March 13, highlighting renewed buy-side interest and momentum flow into the stock. Best Momentum Stocks to Buy for March 13th
• Positive Sentiment: Zacks also listed QTTB among new Strong Buy additions on March 13, reinforcing short-term analyst-driven demand. New Strong Buy Stocks for March 13th
• Neutral Sentiment: Zacks highlights that analysts’ price targets imply a ~103.6% upside vs. the current level — a bullish headline, but the story notes such consensus upside metrics can be unreliable and should be weighed against operational and clinical risk. Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
• Neutral Sentiment: There’s press coverage on HC Wainwright’s Q1 earnings outlook for Q32 Bio; details may influence near-term expectations once parsed by investors. What is HC Wainwright’s Forecast for Q32 Bio Q1 Earnings?
• Negative Sentiment: Despite the analyst upgrades, the sell-side consensus for the current fiscal year remains deeply negative (consensus ~-12.32 EPS), keeping fundamental downside risk and valuation uncertainty elevated — a key reason some investors are selling into rallies.
• Negative Sentiment: Short-term volatility risk remains after the company’s recent unusual EPS print (reported EPS of $3.65 on March 10) and the disparity between that beat and long-term consensus; such divergence can trigger profit-taking and skepticism until guidance/continuity is clear.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.